Pay in 4 interest-free payments of $6.28 Learn more
Ships within 48 hours · Estimated delivery Aug 17 - Aug 22
Like most health insurers, Blue Cross covers medications when medically necessary for patients with type 2 diabetes, including GLP-1s, but does not cover requests for off-label use
The primary endpoint was the occurrence of MACEs, including non-fatal stroke, non-fatal myocardial infarction, hospitalization for heart failure, and cardiovascular death 11
Tirzepatide users had higher success rates for body weight loss and significant weight loss at three, six and 12 months of treatment
The secondary endpoints include achievement of 20% weight reduction, relative change in body weight, change in waist circumference, change in HbA1c, change in systolic blood pressure, change in the quality of life (IWQOL-Lite-CT), and change in short-form physical functioning score (SF-36v2)
US$ 28.47
US$ 23.30
US$ 27.96
US$ 22.11
US$ 26.61
US$ 26.33
US$ 25.76
